R&G PharmaStudies Co (SZSE:301333) Cash-to-Debt : 122.83 (As of Mar. 2024)

R&G PharmaStudies Co Cash-to-Debt Chart

R&G PharmaStudies Co Annual Data
	Trend	Dec13	Dec14	Dec15	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cash-to-Debt		Get a 7-Day Free Trial					No Debt	25.34	32.94	97.07	192.20

R&G PharmaStudies Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															100.77	119.24	141.07	192.20	122.83

Competitive Comparison of R&G PharmaStudies Co's Cash-to-Debt

For the Biotechnology subindustry, R&G PharmaStudies Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

R&G PharmaStudies Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, R&G PharmaStudies Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where R&G PharmaStudies Co's Cash-to-Debt falls into.

R&G PharmaStudies Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

R&G PharmaStudies Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

R&G PharmaStudies Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

R&G PharmaStudies Co  (SZSE:301333) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

R&G PharmaStudies Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of R&G PharmaStudies Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

R&G PharmaStudies Co (SZSE:301333) Business Description